Evaluating the Impact of Lenalidomide on Bone Marrow Cancer Treatment: Monitoring White Blood Cell, Hemoglobin, and Platelet Levels
BACKGROUND: Lenalidomide (LEN), also known as Revlimid, is a drug used to treat multiple myeloma (MM), smoldering myeloma, and myelodysplastic syndromes. It is used as a first-line treatment for MM, along with dexamethasone. OBJECTIVE: To investigate the effects of LEN on the function of bone marrow...
Saved in:
Main Authors: | Hiba Jumaa Hussein, Lara Ali Nazar, Hamsa Ghwamer Ghazi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | Journal of Applied Hematology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/joah.joah_104_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A multiscale model of the bone marrow and hematopoiesis
by: Ariosto Silva, et al.
Published: (2011-03-01) -
Detection of focal lesions in the clot section with negative bone marrow aspirate and trephine biopsy—A series of 5 cases
by: Vandana Bhatti, et al.
Published: (2023-07-01) -
Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies
by: Mengdi Zhang, et al.
Published: (2025-06-01) -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS
by: Maria Teresa Voso, et al.
Published: (2023-08-01) -
The histone demethylase KDM5C enhances the sensitivity of acute myeloid leukemia cells to lenalidomide by stabilizing cereblon
by: Lu Zou, et al.
Published: (2025-01-01)